Table 3.

Univariate logistic regression analysis adjusted for the first-line chemotherapy regimen for POD12.

Prognostic factors	Adverse factors	β	SE	Wald	OR	95% CI		p-value
Sexual distinction	Male	0.61	0.514	1.408	1.841	0.672	5.045	0.235
Age	≥ 60	0.539	0.563	0.916	1.714	0.569	5.169	0.338
Position	Extranodal	0.466	0.51	0.835	1.594	0.586	4.331	0.361
Origin	Non-GCB	0.486	0.545	0.793	1.625	0.558	4.73	0.373
MYC	≥ 40%	0.666	0.559	1.416	1.946	0.65	5.823	0.234
BCL-2	≥ 50%	0.234	0.542	0.185	1.263	0.436	3.658	0.667
BCL-6	≥ 30%	0.205	0.607	0.114	1.227	0.374	4.031	0.736
P53	≥ 50%	0.008	0.513	0	1.008	0.369	2.758	0.987
FMYC	+	0.56	1.252	0.2	1.75	0.15	20.35	0.655
FBCL6	+	1.337	1.184	1.275	3.808	0.374	38.777	0.259
Ki-67	≥ 80%	0.87	0.687	1.604	2.386	0.621	9.169	0.205
LDH (IU/L)	≥ 250	1.379	0.536	6.63	3.973	1.39	11.353	0.01
Seralbumin (g/L)	≥ 40	0.811	0.664	1.491	2.25	0.612	8.27	0.222
AST	≥ 50	0.613	0.95	0.416	1.846	0.287	11.889	0.519
β2-MG	≥ 3	2.167	0.583	13.832	8.73	2.787	27.348	< 0.001
Stage	III, IV	1.089	0.605	3.239	2.971	0.908	9.729	0.072
B symptom	Yes	0.468	0.593	0.623	1.597	0.499	5.108	0.43
Extranodal number	≥ 2	0.806	0.529	2.325	2.24	0.794	6.316	0.127
Bulky	Yes	1.138	0.723	2.476	3.12	0.756	12.873	0.116
ECOG	≥ 2	1.517	0.542	7.823	4.56	1.575	13.205	0.005
R 2	No	0.189	0.69	0.075	1.208	0.312	4.672	0.784
NLR	≥ 1.73	1.284	0.717	3.211	3.611	0.887	14.709	0.073
PLR	≥ 306.494	0.742	0.603	1.514	2.1	0.644	6.846	0.218
SII	≥ 304.2	1.095	0.651	2.825	2.989	0.834	10.717	0.093
LMR	≥ 4.867	0.028	0.666	0.002	1.029	0.279	3.797	0.966